Integra Lifesciences Holdings Overview
Integra Lifesciences Holdings (IART) has a ROE of -0.69%, below the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow-0.69%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Integra Lifesciences Holdings (IART) currently reports a ROE of -0.69%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Integra Lifesciences Holdings's ROE history and peer comparisons.
Integra Lifesciences Holdings's ROE of -0.69% is lower than the Healthcare sector average of 21.67%. That is roughly 103.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Integra Lifesciences Holdings's current -0.69% should be judged against Healthcare norms (sector average: 21.67%) and against IART's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -0.69%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Integra Lifesciences Holdings, and consider following IART for alerts when major investors trade the stock.
Integra Lifesciences Holdings is classified in the Healthcare sector. On ROE, it currently shows -0.69% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IART with unrelated industries.
